Iodine intranasal - BioCide/Symbollon
Alternative Names: NasodineLatest Information Update: 12 Jan 2022
At a glance
- Originator Symbollon Pharmaceuticals
- Developer BioCide Pharma; Symbollon Pharmaceuticals
- Class Anti-infectives; Disinfectants; Halogens; Oxidants
- Mechanism of Action Cell membrane modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections(Prevention) in USA (Inhalation)
- 21 Feb 2011 Preclinical development is ongoing in USA
- 15 Sep 2009 Pharmacodynamics and Adverse event data from preclinical trials in Bacterial infections presented at the Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2009)